121 related articles for article (PubMed ID: 1669441)
1. Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B.
Van Roey P; Bullion KA; Osawa Y; Browne LJ; Bowman RM; Braun DG
J Enzyme Inhib; 1991; 5(2):119-32. PubMed ID: 1669441
[TBL] [Abstract][Full Text] [Related]
2. Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds.
Bullion KA; Osawa Y; Braun DG
Endocr Res; 1990; 16(2):255-67. PubMed ID: 2140551
[TBL] [Abstract][Full Text] [Related]
3. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
4. In vitro potency and selectivity of the non-steroidal androgen aromatase inhibitor CGS 16949A compared to steroidal inhibitors in the brain.
Wozniak A; Holman SD; Hutchison JB
J Steroid Biochem Mol Biol; 1992 Oct; 43(4):281-7. PubMed ID: 1390279
[TBL] [Abstract][Full Text] [Related]
5. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
6. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
[TBL] [Abstract][Full Text] [Related]
7. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
9. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
Purba HS; King EJ; Richert P; Bhatnagar AS
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
[TBL] [Abstract][Full Text] [Related]
10. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Browne LJ; Gude C; Rodriguez H; Steele RE; Bhatnager A
J Med Chem; 1991 Feb; 34(2):725-36. PubMed ID: 1825337
[TBL] [Abstract][Full Text] [Related]
11. Potency and specificity of CGS-16949A as an aromatase inhibitor.
Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
13. Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole.
Recanatini M
J Comput Aided Mol Des; 1996 Feb; 10(1):74-82. PubMed ID: 8786417
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
15. Action of endogenous steroid inhibitors of brain aromatase relative to fadrozole.
Wozniak A; Hutchison JB
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):641-5. PubMed ID: 8476776
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling study of the binding of inhibitors of aromatase to the cytochrome P-450 heme.
Ahmed S; Davis PJ; Owen CP
Drug Des Discov; 1996 Oct; 14(2):91-102. PubMed ID: 9010616
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and aromatase-inhibitory activity of imidazolyl-1,3,5-triazine derivatives.
Matsuno T; Kato M; Tsuchida Y; Takahashi M; Yaguchi S; Terada S
Chem Pharm Bull (Tokyo); 1997 Feb; 45(2):291-6. PubMed ID: 9118443
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships and binding model of novel aromatase inhibitors.
Lang M; Batzl C; Furet P; Bowman R; Häusler A; Bhatnagar AS
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):421-8. PubMed ID: 8476755
[TBL] [Abstract][Full Text] [Related]
20. Effect of the aromatase inhibitor CGS-16949A on pregnancy and secretion of progesterone, estradiol-17beta, prostaglandins E and F2alpha (PGE; PGF2alpha) and pregnancy specific protein B (PSPB) in 90-day ovariectomized pregnant ewes.
Weems YS; Bridges PJ; LeaMaster BR; Sasser RG; Ching L; Weems CW
Prostaglandins Other Lipid Mediat; 2001 Sep; 66(2):77-88. PubMed ID: 11529553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
